Васюк ю а сердечная недостаточность

Вариабельность сердечного ритма в оценке клинико-функционального состояния и прогноза при хронической сердечной недостаточности

Васюк ю а сердечная недостаточность

1. Breithardt G. Foreword. Eur. Heart J. 2002;4:1-2

2. McMurray J.J.V., Stewart S. Epidemiology, aetiology and prognosis of heart failure. Heart. 2000;83:596-602

3. Беленков Ю.Н., Агеев Ф.Т. и соавт. Эпидемиология и прогноз хронической сердечной недостаточности. Русский медицинский журнал 1999;2:51-56

4. Беленков Ю.Н. Классификация хронической сердечной недостаточности. Сердечная недостаточность 2001;6:249-251

5. Лопатин Ю.М. Симпатико-адреналовая система при сердечной недостаточности: роль в патогенезе, возможности коррекции. Сердечная недостаточность 2002;1:20-21

6. Ferrari R., Ceconi C. Neuroendocrine activation in left ventricular dysfunction. Eur.Heart J. 1998;19:1423-1424

7. Макаров Л.М. Холтеровское мониторирование. М.: Медпрактика-М, 2003:65-115

8. Staessen L., Bieniaszewski L. Nosturnal blood pressure fall on ambulatory monitoring in a large international database. Hypertension. 1997;1:30-39

9. Casolo G., Balli E., Taddei T. Decreased spontaneous heart rate variability in congestive heart failure. Amer. J.Cardiol. 1989;15:1162- 1167

10. Дабровски А., Дабровски Б., Пиотрович П. Суточное мониторирование ЭКГ. М.: Медпрактика, 1998:208с.

11. Иванов Г.Г. Вариабельность сердечного ритма. «Современная электрокардиография: новые возможности и области применения в клинике» Сб. науч. трудов. М., 2000:24-27

12. Баевский Р.М. Анализ вариабельности сердечного ритма при использовании различных электрокардиографических систем: Метод. рек. М., 2002:487-513

13. Михайлов В.М. Вариабельность сердечного ритма. Опыт практического применения. Иваново, 2000:200с.

14. Umetani K., Singer D. 24 hour time domain heart rate variability and heart rate: relation to age and gender over nine decades. JACC. 1999;31:593-601

15. Nolan J., Batin P.D., Andrews R. Prospective study of heart rate variability and mortality in chronic heart failure. Circulation. 1998;98: 1510-1516

16. Galinier M., Pathak A., Fourcade J. Depressed low frequency power of heart rate variability as an independent predictor of sudden death in chronic heart failure. Eur.Heart J. 2000;6:475-482

17. Bigger T.J., Fleiss J.L., Steinman R.C. Heart rate variability in healthy middle-aged persons compared with patients with chronic coronary heart disease or recent acute myocardial infarction. Circulation 1995; 21: 245-311

18. Goldberg J., Kadish A. Influence of sympathetic and parasympathetic maneuvers on heart rate variability. In: Noninvasive Electrocardiology. Clinical Aspects of Holter Monitoring. Moss A., Stern S. 1997: 207-223

19. Ramaekers D., Ector H., Aubert A. Heart rate variability and heart rate in healthy volunteers. Eur. Heart J. 1998;19:1334-1341

20. Bonaduce D., Petretta M., Marciano F. Independent and incremental prognostic value of heart rate variability in patients with heart failure. Amer. Heart J. 1999;8:138-145

21. Woo M.A., Stevenson W.G. Patterns of beat-to-beat heart rate variability in advanced heart failure. Amer. J. Cardiol. 1992;123:704- 710

22. Флейшман А.Н. Медленные колебания гемодинамики. Новосибирск,1999:264 c.

23. Mortara A., Sleight P., Pinna G.D. Abnormal awake respiratory patterns are common in chronic heart failure and may prevent evaluation of autonomic tone by measures of heart rate variability. Circulation. 1997;96:246-252

24. Ponikowski P., Anker S.D., Chua T.P. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. JACC. 1997;79:1645-1650

25. Guzzetti S., La Rovere M.T., Pinna G.D. Different spectral components of 24 h heart rate variability are related to different modes of death in chronic heart failure. Eur.Heart J. 2004;26:357-362

26. Беленков Ю.Н., Мареев В.Ю., Скворцов А.А. Эналаприл против карведилола. Сравнительное рандомизированное исследование у больных с хронической сердечной недостаточностью (ЭК- СТАЗ). Сердечная недостаточность 2001;2:23-25

27. Keeley E.C., Page R.L., Lange R.A. Influence of metoprolol on heart rate variability in survivors of remote myocardial infarction. Am.J.Cardiol. 1996;77:557-560

28. Zhang Y.H., Song Y.C., Zhu J. Effects of enalapril on heart rate variability in patients with congestive heart failure. Am. J. Cardiol. 1995;76:1045-1048

29. Ulgen M.S., Akdemir O., Toprac N. The effects of trimetazidine on heart rate variability and signal average electrocardiography in early period of acute myocardial infarction. Int. J. Cardiol. 2001;7:255- 262

30. Давиташвили И.М., Кобалава Ж.Д., Климиашвили А. Действие препарата предуктал на параметры вариабельности ритма сердца у больных с инфарктом миокарда. Материалы Всероссийского научно-практического семинара «Современные возможности холтеровского мониторирования». Санкт-Петербург , 25-29 мая 2000 г. 12c.

Источник: //www.rpcardio.com/jour/article/view/1021?locale=ru_RU

Натрийуретические пептиды и хроническая сердечная недостаточность у больных артериальной гипертензией

Васюк ю а сердечная недостаточность

1. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325: 293-302.

2. MERIT4HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT4HF). Lancet 1999; 353: 293-302.

3. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.

4. Агеев Ф.Т., Даниелян М.О., Мареев Ю.В., Беленков Ю.Н. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА4О4ХСН). Серд недостат 2004; 1: 4-7.

5. Vasan RS, Benjamin EL, Levy D. Congestive heart failure with normal left ventricular systolic function: clinical approaches to the diagnosis and treatment of diastolic heart failure. Arch Intern Med 1996; 156(2): 146-65.

6. Slama M, Susic D, Varagic J, et al. Diastolic dysfunction in hypertension. Curr Opin Cardiol 2002; 17: 368-73.

7. Lerman A, Gibbons RJ, Rodeheffer RJ. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet 1993; 341: 1105-9.

8. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994; 343: 440-4.

9. Levin RE, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: 321-8.

10. Melo LG, Pang SC, Ackermann U. Atrial natriuretic peptide: regulator of chronic arterial blood pressure. News Physiol Sci 2000; 15: 143-9.

11. De Bold AJ, Bruneau BG, De Bold K. Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 1996; 31: 7-18.

12. Kinnunen P, Vuolteenaho O, Ruskoah H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132: 1961-70.

13. Richards AM, Crozier JG, Yandle TG, et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993; 69: 414-7.

14. Haug C, Metzele A, Kochs M, et al. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end4diastolic pressure. Clin Cardiol 1993; 15: 553-7.

15. JC, Glants SA. Determinants of left ventricular filling and of the diastolic pressure-volume relaxation. Circ Res 1989; 64: 827-52.

16. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dys4 function. Am Heart J 1998; 135: 825-32.

17. Iwanaga Y, Nishi I, Furuichi S, et al. B-Type Natriuretic Peptide Strongly Reflects Diastolic Wall Stress in Patients With Chronic Heart Failure. Comparison Between Systolic and Diastolic Heart Failure. JACC 2006; 47: 742-8.

18. Hannah A, Clements S, McDonagh TA, et al. Low prevalence of isolated diastolic dysfunction in a cohort of suspected heart failure patients ant its relationship to brain natriuretic peptide. Eur Heart J 2003; 24 Abstract (Suppl.): 400.

19. Lubien E., DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.

20. Thambidorai SK, Troughton RW, Parakh K, et al. Utility of B-type natriuretic peptide in primary diastolic dysfunction: a quantitative comparison with Doppler echocardiographic indices. JACC 2003; 24 Abstract (Suppl.): 400.

21. Bettencourt P, Ferreira A, Dias P, et al. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology 2000; 93: 19-21.

22. Yamamoto K, Burnett JCJr, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996; 28: 988-94.

23. Yamaguchi H, Yoshida K, Sakata Y. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. Am J Cardiol 2004; 43: 55-60.

24. Schillaci G, Verdecchia P, Porcellati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-6.

25. Devereux RB, Roman MJ, Liu JE, et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the strong heart study. Am J Cardiology 2000; 86: 1090-6.

26. O`Connor CM, Gattis WA, Shaw L, et al. Clinical characteristics and long-term outcome of patients with heart failure and preserved systolic function. Am J Cardiol 2000; 86: 863-7.

27. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992; 92: 29-34.

28. Luchner A, Burnett JCJr, Jougasaki M, et al. Evaluation of brain natriuretic peptide as a marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000; 18: 1121-8.

29. Suzuki M, Yamamoto K, Watanabe S, et al. Associates between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with essential hyperten4 sion. Am J Med 2000; 108: 627-33.

30. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30.

31. Sakata Y, Yamamoto K, Masuyama T, et al. Ventricular production of natriuretic peptides and ventricular structural remodeling in hypertensive heart failure. J Hypertens 2001; 19: 1905-12.

32. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for a exquisite dual natriuretic peptide system? J Clin Invest 1991; 87: 1402-12.

33. Kohno M, Minami M, Kano H, et al. Effect of angiotensin-converting enzyme inhibitor on left ventricular parameters and circulating brain natriuretic peptide in elderly hypertensives with left ventricular hypertrophy. Metabolism 2000; 49: 1356-60.

Том 6, № 2 (2007)

//doi.org/10.15829/1728-8800-2007-2
Контент доступен под лицензией Creative Commons Attribution 4.0 License. ISSN 1728-8800 (Print)ISSN 2619-0125 (Online)

Источник: //cardiovascular.elpub.ru/jour/article/view/1208

Мудрый Врач
Добавить комментарий